{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:08:47Z","timestamp":1790766527465,"version":"4.1.0"},"reference-count":130,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T00:00:00Z","timestamp":1632700800000},"content-version":"vor","delay-in-days":238,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002426","name":"Fondazione Telethon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002426","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001245","name":"Jeffrey Modell Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001245","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ymthe.2020.11.020","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T09:50:30Z","timestamp":1605865830000},"page":"489-504","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"title":["Update on Clinical Ex\u00a0Vivo Hematopoietic Stem Cell Gene Therapy for Inherited Monogenic Diseases"],"prefix":"10.1016","volume":"29","author":[{"given":"Francesca","family":"Tucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Scaramuzza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5398-1717","authenticated-orcid":false,"given":"Alessandro","family":"Aiuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Mortellaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2020.11.020_bib1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/1744666X.2018.1424627","article-title":"Hematopoietic cell transplantation in primary immunodeficiency\u2013conventional and emerging indications","volume":"14","author":"Slatter","year":"2018","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.ymthe.2020.11.020_bib2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3389\/fped.2019.00433","article-title":"Hematopoietic stem cell transplantation in inborn errors of metabolism","volume":"7","author":"Tan","year":"2019","journal-title":"Front Pediatr."},{"key":"10.1016\/j.ymthe.2020.11.020_bib3","doi-asserted-by":"crossref","first-page":"97ra80","DOI":"10.1126\/scitranslmed.3002716","article-title":"Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction","volume":"3","author":"Gaspar","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2020.11.020_bib4","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa0805817","article-title":"Gene therapy for immunodeficiency due to adenosine deaminase deficiency","volume":"360","author":"Aiuti","year":"2009","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2020.11.020_bib5","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.1088547","article-title":"LMO2-associated clonal T\u00a0cell proliferation in two patients after gene therapy for SCID-X1","volume":"302","author":"Hacein-Bey-Abina","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2020.11.020_bib6","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1172\/JCI35798","article-title":"Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients","volume":"118","author":"Howe","year":"2008","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2020.11.020_bib7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/83324","article-title":"Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics","volume":"7","author":"Kay","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2020.11.020_bib8","doi-asserted-by":"crossref","first-page":"737","DOI":"10.15252\/emmm.201707573","article-title":"Gene therapy for ADA-SCID, the first marketing approval of an ex\u00a0vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products","volume":"9","author":"Aiuti","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymthe.2020.11.020_bib9","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1089\/hum.2017.175","article-title":"Twenty-five years of gene therapy for ADA-SCID: from bubble babies to an approved drug","volume":"28","author":"Ferrua","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2020.11.020_bib10","unstructured":"Orchard Therapeutics. Strimvelis guidelines. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/strimvelis-epar-product-information_en.pdf."},{"key":"10.1016\/j.ymthe.2020.11.020_bib11","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/cpt.1639","article-title":"Regulators\u2019 advice can make a difference: European Medicines Agency approval of Zynteglo for beta thalassemia","volume":"107","author":"Schuessler-Lenz","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ymthe.2020.11.020_bib12","series-title":"New gene therapy to treat rare genetic disorder metachromatic leukodystrophy","year":"2020"},{"key":"10.1016\/j.ymthe.2020.11.020_bib13","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3389\/fped.2019.00295","article-title":"Hematopoietic stem cell transplantation in primary immunodeficiency diseases: current status and future perspectives","volume":"7","author":"Castagnoli","year":"2019","journal-title":"Front Pediatr."},{"key":"10.1016\/j.ymthe.2020.11.020_bib14","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1126\/science.288.5466.669","article-title":"Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease","volume":"288","author":"Cavazzana-Calvo","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2020.11.020_bib15","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJMoa012616","article-title":"Sustained correction of X-linked severe combined immunodeficiency by ex\u00a0vivo gene therapy","volume":"346","author":"Hacein-Bey-Abina","year":"2002","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2020.11.020_bib16","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(04)17590-9","article-title":"Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector","volume":"364","author":"Gaspar","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2020.11.020_bib17","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1016\/S2352-3026(19)30021-3","article-title":"Lentiviral haemopoietic stem\/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1\/2 clinical study","volume":"6","author":"Ferrua","year":"2019","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.ymthe.2020.11.020_bib18","doi-asserted-by":"crossref","first-page":"1233158","DOI":"10.1126\/science.1233158","article-title":"Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy","volume":"341","author":"Biffi","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2020.11.020_bib19","doi-asserted-by":"crossref","first-page":"335ra57","DOI":"10.1126\/scitranslmed.aad8856","article-title":"Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency","volume":"8","author":"De Ravin","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2020.11.020_bib28","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1815408","article-title":"Lentiviral gene therapy combined with low-dose busulfan in infants with SCID-X1","volume":"380","author":"Mamcarz","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2020.11.020_bib29","doi-asserted-by":"crossref","first-page":"1233151","DOI":"10.1126\/science.1233151","article-title":"Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome","volume":"341","author":"Aiuti","year":"2013","journal-title":"Science"},{"issue":"Suppl 1","key":"10.1016\/j.ymthe.2020.11.020_bib20","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1182\/blood-2019-123432","article-title":"Lentiviral gene therapy with autologous hematopoietic stem and progenitor cells (HSPCs) for the treatment of severe combined immune deficiency due to adenosine deaminase deficiency (ADA-SCID): results in an expanded cohort","volume":"134","author":"Kohn","year":"2019","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.ymthe.2020.11.020_bib21","doi-asserted-by":"crossref","first-page":"4629","DOI":"10.1182\/blood-2019-126161","article-title":"Outcome of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome","volume":"134","author":"Labrosse","year":"2019","journal-title":"Blood"},{"issue":"4S1","key":"10.1016\/j.ymthe.2020.11.020_bib127","article-title":"Long-term follow-up study after lentiviral hematopoietic stem\/progenitor cell gene therapy for Wiskott-Aldrich syndrome.","volume":"28","author":"Magnani","year":"2020","journal-title":"Mol. Therapy"},{"key":"10.1016\/j.ymthe.2020.11.020_bib22","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41591-019-0735-5","article-title":"Lentiviral gene therapy for X-linked chronic granulomatous disease","volume":"26","author":"Kohn","year":"2020","journal-title":"Nat. Med."},{"issue":"4S1","key":"10.1016\/j.ymthe.2020.11.020_bib128","article-title":"Results from a phase I\/II clinical trial for X linked chronic granulomatous disease (CGD).","volume":"48","author":"Magnani","year":"2020","journal-title":"Mol. Therapy"},{"issue":"4S1","key":"10.1016\/j.ymthe.2020.11.020_bib129","article-title":"Clinical outcomes from a phase I\/II gene therapy trial for patients affected by severe transfusion dependent beta-thalassemia: Two years follow up.","volume":"28","author":"Scaramuzza","year":"2020","journal-title":"Mol. Therapy"},{"issue":"Suppl 1","key":"10.1016\/j.ymthe.2020.11.020_bib23","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1182\/blood-2019-126046","article-title":"Northstar-2: updated safety and efficacy analysis of lentiglobin gene therapy in patients with transfusion-dependent \u03b2-thalassemia and non-\u03b20\/\u03b20 genotypes","volume":"134","author":"Thompson","year":"2019","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.ymthe.2020.11.020_bib24","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1182\/blood-2019-128482","article-title":"Northstar-3: interim results from a phase 3 study evaluating lentiglobin gene therapy in patients with transfusion-dependent beta-thalassemia and either a beta0 or ivs-i-110 mutation at both alleles of the HBB gene","volume":"134","author":"Lal","year":"2019","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.ymthe.2020.11.020_bib25","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1182\/blood-2019-127393","article-title":"Results from the completed Hgb-205 trial of lentiglobin for \u03b2-thalassemia and lentiglobin for sickle cell disease gene therapy","volume":"134","author":"Magrin","year":"2019","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.ymthe.2020.11.020_bib26","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1182\/blood-2019-128814","article-title":"Exploring the drivers of potential clinical benefit in initial patients treated in the Hgb-206 study of lentiglobin for sickle cell disease (SCD) gene therapy","volume":"134","author":"Walters","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.11.020_bib27","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1056\/NEJMoa1700554","article-title":"Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy","volume":"377","author":"Eichler","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"4S1","key":"10.1016\/j.ymthe.2020.11.020_bib130","article-title":"Preliminary outcomes of haematopoietic stem cell gene therapy in a patient with mucopolysaccharidosis IIIA.","volume":"28","author":"Kinsella","year":"2020","journal-title":"Mol. Therapy"},{"key":"10.1016\/j.ymthe.2020.11.020_bib30","doi-asserted-by":"crossref","first-page":"eaan0820","DOI":"10.1126\/scitranslmed.aan0820","article-title":"Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1","volume":"9","author":"Schiroli","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2020.11.020_bib31","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1038\/s41467-019-09614-y","article-title":"Gene correction for SCID-X1 in long-term hematopoietic stem cells","volume":"10","author":"Pavel-Dinu","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2020.11.020_bib32","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13023-018-0807-5","article-title":"Adenosine deaminase deficiency: a review","volume":"13","author":"Flinn","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymthe.2020.11.020_bib33","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3389\/fimmu.2016.00314","article-title":"Adenosine deaminase deficiency\u2014more than just an immunodeficiency","volume":"7","author":"Whitmore","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2020.11.020_bib34","doi-asserted-by":"crossref","first-page":"S228","DOI":"10.1016\/S0090-1229(95)90306-2","article-title":"PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years","volume":"76","author":"Hershfield","year":"1995","journal-title":"Clin. Immunol. Immunopathol."},{"key":"10.1016\/j.ymthe.2020.11.020_bib35","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.jaci.2018.08.024","article-title":"Consensus approach for the management of severe combined immune deficiency caused by adenosine deaminase deficiency","volume":"143","author":"Kohn","year":"2019","journal-title":"J.\u00a0Allergy Clin. Immunol."},{"key":"10.1016\/j.ymthe.2020.11.020_bib36","first-page":"462","article-title":"Suppression of an antibody to adenosine-deaminase (ADA) in an ADA-deficient patient receiving polyethylene glycol modified adenosine deaminase","volume":"70","author":"Chun","year":"1993","journal-title":"Ann. Allergy"},{"key":"10.1016\/j.ymthe.2020.11.020_bib37","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3389\/fimmu.2018.00113","article-title":"First occurrence of plasmablastic lymphoma in adenosine deaminase-deficient severe combined immunodeficiency disease patient and review of the literature","volume":"9","author":"Migliavacca","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2020.11.020_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40124-014-0071-7","article-title":"Hematopoietic stem cell transplantation for severe combined immunodeficiency","volume":"3","author":"Wahlstrom","year":"2015","journal-title":"Curr. Pediatr. Rep."},{"key":"10.1016\/j.ymthe.2020.11.020_bib39","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1126\/science.1070104","article-title":"Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning","volume":"296","author":"Aiuti","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2020.11.020_bib40","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2016-01-688226","article-title":"Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency","volume":"128","author":"Cicalese","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.11.020_bib41","series-title":"Potential adverse reaction to gene therapy in a patient treated with Strimvelis for the treatment of ADA-SCID","year":"2020"},{"key":"10.1016\/j.ymthe.2020.11.020_bib42","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1172\/JCI90367","article-title":"Clinical efficacy of gene-modified stem cells in adenosine deaminase-deficient immunodeficiency","volume":"127","author":"Shaw","year":"2017","journal-title":"J.\u00a0Clin. Invest."},{"issue":"Suppl 1","key":"10.1016\/j.ymthe.2020.11.020_bib43","first-page":"S106","article-title":"Immunological and metabolic correction after lentiviral vector mediated haematopoietic stem cell gene therapy for ADA deficiency","volume":"22","author":"Gaspar","year":"2014","journal-title":"J.\u00a0Clin. Immunol."},{"key":"10.1016\/j.ymthe.2020.11.020_bib44","first-page":"364","article-title":"Gene therapy for adenosine deaminase-deficient severe combined immunodeficiency (ADA SCID) with a lentiviral vector","volume":"38","author":"Kohn","year":"2018","journal-title":"J.\u00a0Clin. Immunol."},{"key":"10.1016\/j.ymthe.2020.11.020_bib45","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10875-017-0453-z","article-title":"Clinical manifestations and pathophysiological mechanisms of the Wiskott-Aldrich syndrome","volume":"38","author":"Candotti","year":"2018","journal-title":"J.\u00a0Clin. Immunol."},{"key":"10.1016\/j.ymthe.2020.11.020_bib46","doi-asserted-by":"crossref","first-page":"103919","DOI":"10.1016\/j.cellimm.2019.04.007","article-title":"The role of WASp in T\u00a0cells and B cells","volume":"341","author":"Sun","year":"2019","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.ymthe.2020.11.020_bib47","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3389\/fped.2019.00445","article-title":"Hematopoietic stem cell transplantation for primary immunodeficiencies","volume":"7","author":"Gennery","year":"2019","journal-title":"Front Pediatr."},{"key":"10.1016\/j.ymthe.2020.11.020_bib48","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1056\/NEJMoa1003548","article-title":"Stem-cell gene therapy for the Wiskott-Aldrich syndrome","volume":"363","author":"Boztug","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2020.11.020_bib49","doi-asserted-by":"crossref","first-page":"227ra33","DOI":"10.1126\/scitranslmed.3007280","article-title":"Gene therapy for Wiskott-Aldrich syndrome\u2014long-term efficacy and genotoxicity","volume":"6","author":"Braun","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2020.11.020_bib50","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jaci.2020.06.018","article-title":"Gene therapy for Wiskott-Aldrich syndrome: history, new vectors, future directions","volume":"146","author":"Ferrua","year":"2020","journal-title":"J.\u00a0Allergy Clin. Immunol."},{"key":"10.1016\/j.ymthe.2020.11.020_bib51","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.ymthe.2004.08.008","article-title":"Lentiviral vector-mediated gene transfer in T\u00a0cells from Wiskott-Aldrich syndrome patients leads to functional correction","volume":"10","author":"Dupr\u00e9","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.11.020_bib52","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jaci.2019.03.012","article-title":"Lentiviral gene therapy corrects platelet phenotype and function in patients with Wiskott-Aldrich syndrome","volume":"144","author":"Sereni","year":"2019","journal-title":"J.\u00a0Allergy Clin. Immunol."},{"key":"10.1016\/j.ymthe.2020.11.020_bib53","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1001\/jama.2015.3253","article-title":"Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome","volume":"313","author":"Hacein-Bey Abina","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ymthe.2020.11.020_bib54","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1182\/blood-2017-04-777136","article-title":"Gene therapy for Wiskott-Aldrich syndrome in a severely affected adult","volume":"130","author":"Morris","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.11.020_bib55","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1038\/s41591-018-0195-3","article-title":"Dynamics of genetically engineered hematopoietic stem and progenitor cells after autologous transplantation in humans","volume":"24","author":"Scala","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2020.11.020_bib56","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1182\/blood.2019002350","article-title":"Clonal tracking in gene therapy patients reveals a diversity of human hematopoietic differentiation programs","volume":"135","author":"Six","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.11.020_bib57","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1182\/blood.2019000021","article-title":"Two decades of excellent transplant survival for chronic granulomatous disease: a supraregional immunology transplant center report","volume":"133","author":"Lum","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.11.020_bib58","doi-asserted-by":"crossref","first-page":"12133","DOI":"10.1073\/pnas.94.22.12133","article-title":"Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease","volume":"94","author":"Malech","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2020.11.020_bib59","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nm1393","article-title":"Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1","volume":"12","author":"Ott","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2020.11.020_bib60","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1038\/mt.2011.166","article-title":"Retroviral gene therapy for X-linked chronic granulomatous disease: results from phase I\/II trial","volume":"19","author":"Kang","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.11.020_bib61","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nm.2088","article-title":"Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease","volume":"16","author":"Stein","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2020.11.020_bib62","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood-2009-05-222760","article-title":"Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils","volume":"115","author":"Kang","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.11.020_bib63","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2174\/1566523215666150515145255","article-title":"Successful combination of sequential gene therapy and rescue allo-HSCT in two children with X-CGD\u2014importance of timing","volume":"15","author":"Siler","year":"2015","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.ymthe.2020.11.020_bib64","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/mt.2010.226","article-title":"Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells","volume":"19","author":"Santilli","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.11.020_bib65","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/humc.2017.245","article-title":"Non-clinical efficacy and safety studies on G1XCGD, a lentiviral vector for ex\u00a0vivo gene therapy of X-linked chronic granulomatous disease","volume":"29","author":"Brendel","year":"2018","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.ymthe.2020.11.020_bib66","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/mt.2014.87","article-title":"Dual-regulated lentiviral vector for gene therapy of X-linked chronic granulomatosis","volume":"22","author":"Chiriaco","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.11.020_bib67","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1038\/mt.2016.150","article-title":"Lentiviral vector gene therapy protects XCGD mice from acute Staphylococcus aureus pneumonia and inflammatory response","volume":"24","author":"Farinelli","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.11.020_bib68","article-title":"Hematopoietic tumors in a mouse model of X-linked chronic granulomatous disease after lentiviral vector-mediated gene therapy","author":"Jofra Hern\u00e1ndez","year":"2020","journal-title":"Mol. Ther"},{"key":"10.1016\/j.ymthe.2020.11.020_bib69","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1016\/S2214-109X(13)70150-5","article-title":"Global migration and the changing distribution of sickle haemoglobin: a quantitative study of temporal trends between 1960 and 2000","volume":"2","author":"Piel","year":"2014","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.ymthe.2020.11.020_bib70","doi-asserted-by":"crossref","first-page":"480","DOI":"10.2471\/BLT.06.036673","article-title":"Global epidemiology of haemoglobin disorders and derived service indicators","volume":"86","author":"Modell","year":"2008","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.ymthe.2020.11.020_bib71","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0140-6736(17)31822-6","article-title":"Thalassaemia","volume":"391","author":"Taher","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2020.11.020_bib72","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/bmt.2015.293","article-title":"Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000\u20132010","volume":"51","author":"Baronciani","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.ymthe.2020.11.020_bib73","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3324\/haematol.2013.099747","article-title":"Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel","volume":"99","author":"Angelucci","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.ymthe.2020.11.020_bib74","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1146\/annurev-pathmechdis-012418-012838","article-title":"Pathophysiology of sickle cell disease","volume":"14","author":"Sundd","year":"2019","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.ymthe.2020.11.020_bib75","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3324\/haematol.2010.031013","article-title":"Quantitatively different red cell\/nucleated cell chimerism in patients with long-term, persistent hematopoietic mixed chimerism after bone marrow transplantation for thalassemia major or sickle cell disease","volume":"96","author":"Andreani","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.ymthe.2020.11.020_bib76","doi-asserted-by":"crossref","first-page":"10547","DOI":"10.1073\/pnas.0711666105","article-title":"In\u00a0vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of beta-thalassemia","volume":"105","author":"Miccio","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2020.11.020_bib77","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/emmm.201000083","article-title":"Correction of \u03b2-thalassemia major by gene transfer in haematopoietic progenitors of pediatric patients","volume":"2","author":"Roselli","year":"2010","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymthe.2020.11.020_bib78","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.1182\/blood-2003-04-1251","article-title":"Correction of a mouse model of sickle cell disease: lentiviral\/antisickling \u03b2-globin gene transduction of unmobilized, purified hematopoietic stem cells","volume":"102","author":"Levasseur","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.11.020_bib79","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1126\/science.1065806","article-title":"Correction of sickle cell disease in transgenic mouse models by gene therapy","volume":"294","author":"Pawliuk","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2020.11.020_bib80","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ymthe.2019.09.020","article-title":"Improved titer and gene transfer by lentiviral vectors using novel, small \u03b2-globin locus control region elements","volume":"28","author":"Morgan","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.11.020_bib81","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1172\/JCI123191","article-title":"Bone marrow stromal cells from \u03b2-thalassemia patients have impaired hematopoietic supportive capacity","volume":"129","author":"Crippa","year":"2019","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2020.11.020_bib82","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1182\/blood.2019002721","article-title":"Hematopoietic stem cell function in \u03b2-thalassemia is impaired and is rescued by targeting the bone marrow niche","volume":"136","author":"Aprile","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.11.020_bib83","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1182\/blood.2019002227","article-title":"Pathologic angiogenesis in the bone marrow of humanized sickle cell mice is reversed by blood transfusion","volume":"135","author":"Park","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.11.020_bib84","first-page":"126","article-title":"Stem cell transplantation and gene therapy for hemoglobinopathies","volume":"4","author":"Gaziev","year":"2005","journal-title":"Curr. Hematol. Rep."},{"key":"10.1016\/j.ymthe.2020.11.020_bib85","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nature09328","article-title":"Transfusion independence and HMGA2 activation after gene therapy of human \u03b2-thalassaemia","volume":"467","author":"Cavazzana-Calvo","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2020.11.020_bib86","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1056\/NEJMoa1705342","article-title":"Gene therapy in patients with transfusion-dependent \u03b2-thalassemia","volume":"378","author":"Thompson","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2020.11.020_bib87","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41591-018-0301-6","article-title":"Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent \u00df-thalassemia","volume":"25","author":"Marktel","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2020.11.020_bib88","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJMoa1609677","article-title":"Gene Therapy in a patient with sickle cell disease","volume":"376","author":"Ribeil","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"Suppl 1","key":"10.1016\/j.ymthe.2020.11.020_bib89","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1182\/blood-2019-128894","article-title":"Resolution of sickle cell disease manifestations in patients treated with lentiglobin gene therapy: updated results from the phase 1\/2 Hgb-206 group C study","volume":"134","author":"Kanter","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.11.020_bib90","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/blood-2013-09-528067","article-title":"Fetal hemoglobin in sickle cell anemia: a glass half full?","volume":"123","author":"Steinberg","year":"2014","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.ymthe.2020.11.020_bib91","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1182\/blood-2018-99-119591","article-title":"Gene therapy for sickle cell anemia using a modified gamma globin lentivirus vector and reduced intensity conditioning transplant shows promising correction of the disease phenotype","volume":"132","author":"Malik","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.11.020_bib92","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.2174\/138161208784705504","article-title":"Lysosomal storage diseases and the blood-brain barrier","volume":"14","author":"Begley","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ymthe.2020.11.020_bib93","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1093\/hmg\/ddi126","article-title":"Enzyme replacement improves nervous system pathology and function in a mouse model for metachromatic leukodystrophy","volume":"14","author":"Matzner","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2020.11.020_bib94","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1172\/JCI28873","article-title":"Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice","volume":"116","author":"Biffi","year":"2006","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2020.11.020_bib95","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1089\/hum.2007.048","article-title":"Safety of arylsulfatase A overexpression for gene therapy of metachromatic leukodystrophy","volume":"18","author":"Capotondo","year":"2007","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2020.11.020_bib96","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41593-019-0545-6","article-title":"The influence of environment and origin on brain resident macrophages and implications for therapy","volume":"23","author":"Bennett","year":"2020","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ymthe.2020.11.020_bib97","doi-asserted-by":"crossref","first-page":"14821","DOI":"10.1073\/pnas.93.25.14821","article-title":"Phenotype of arylsulfatase A-deficient mice: relationship to human metachromatic leukodystrophy","volume":"93","author":"Hess","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2020.11.020_bib98","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1073\/pnas.252784899","article-title":"Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB","volume":"100","author":"Ohmi","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2020.11.020_bib99","doi-asserted-by":"crossref","first-page":"10954","DOI":"10.1073\/pnas.97.20.10954","article-title":"Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation","volume":"97","author":"Wada","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2020.11.020_bib100","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1002\/glia.23598","article-title":"Microglia damage precedes major myelin breakdown in X-linked adrenoleukodystrophy and metachromatic leukodystrophy","volume":"67","author":"Bergner","year":"2019","journal-title":"Glia"},{"key":"10.1016\/j.ymthe.2020.11.020_bib101","first-page":"109","article-title":"The genetic landscape of X-linked adrenoleukodystrophy: inheritance, mutations, modifier genes, and diagnosis","volume":"8","author":"Wiesinger","year":"2015","journal-title":"Appl. Clin. Genet."},{"key":"10.1016\/j.ymthe.2020.11.020_bib102","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/j.1471-4159.1976.tb04461.x-i1","article-title":"Fatty acid abnormality in adrenoleukodystrophy","volume":"26","author":"Igarashi","year":"1976","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ymthe.2020.11.020_bib103","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S1474-4422(07)70177-1","article-title":"Survival analysis of haematopoietic cell transplantation for childhood cerebral X-linked adrenoleukodystrophy: a comparison study","volume":"6","author":"Mahmood","year":"2007","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2020.11.020_bib104","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.bbmt.2018.09.036","article-title":"Survival and functional outcomes in boys with cerebral adrenoleukodystrophy with and without hematopoietic stem cell transplantation","volume":"25","author":"Raymond","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.ymthe.2020.11.020_bib105","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bbmt.2016.10.019","article-title":"Allele-level HLA matching impacts key outcomes following umbilical cord blood transplantation for inherited metabolic disorders","volume":"23","author":"Mallhi","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.ymthe.2020.11.020_bib106","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.1171242","article-title":"Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy","volume":"326","author":"Cartier","year":"2009","journal-title":"Science"},{"issue":"4S1","key":"10.1016\/j.ymthe.2020.11.020_bib107","article-title":"Continuing clinical efficacy and ALDP gene expression 5\u201310 years after lentiviral LV-based CD34+ cell gene therapy in patients with X-linked adrenoleukodystrophy (X-ALD)","volume":"28","author":"Aubourg","year":"2020","journal-title":"Mol. Ther."},{"issue":"4S1","key":"10.1016\/j.ymthe.2020.11.020_bib108","article-title":"Long term follow-up of integration profiles in subjects enrolled in the first SIN-LV gene therapy trial for treatment of X-adrenoleukodystrophy","volume":"28","author":"Labik","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.11.020_bib109","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1651-2227.2008.00648.x","article-title":"Metachromatic leukodystrophy: genetics, pathogenesis and therapeutic options","volume":"97","author":"Gieselmann","year":"2008","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.ymthe.2020.11.020_bib110","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13023-015-0313-y","article-title":"Long-term outcomes after allogeneic hematopoietic stem cell transplantation for metachromatic leukodystrophy: the largest single-institution cohort report","volume":"10","author":"Boucher","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymthe.2020.11.020_bib111","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1172\/JCI200419205","article-title":"Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells","volume":"113","author":"Biffi","year":"2004","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2020.11.020_bib112","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/j.ymgme.2019.11.135","article-title":"Lentiviral hematopoietic stem and progenitor cell gene therapy (HSPC-GT) for metachromatic leukodystrophy (MLD): clinical outcomes from 33 patients","volume":"129","author":"Fumagalli","year":"2020","journal-title":"Mol. Genet. Metab"},{"issue":"Suppl","key":"10.1016\/j.ymthe.2020.11.020_bib113","first-page":"234","article-title":"Late phases of hematopoietic reconstitution in metachromatic leukodystrophy gene therapy patients are characterized by lineage commitment of individual HSC clones","volume":"28","author":"Calabria","year":"2020","journal-title":"Mol. Ther"},{"key":"10.1016\/j.ymthe.2020.11.020_bib114","series-title":"The Metabolic and Molecular Bases of Inherited Diseases","first-page":"3421","article-title":"The mucopolysaccharidoses","author":"Neufeld","year":"2001"},{"key":"10.1016\/j.ymthe.2020.11.020_bib115","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.ymthe.2004.03.011","article-title":"Correction of metabolic, craniofacial, and neurologic abnormalities in MPS I mice treated at birth with adeno-associated virus vector transducing the human alpha-L-iduronidase gene","volume":"9","author":"Hartung","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.11.020_bib116","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.ymthe.2004.10.006","article-title":"Neonatal gene therapy of MPS I mice by intravenous injection of a lentiviral vector","volume":"11","author":"Kobayashi","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.11.020_bib117","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ymgme.2015.06.002","article-title":"Neurocognition across the spectrum of mucopolysaccharidosis type I: age, severity, and treatment","volume":"116","author":"Shapiro","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2020.11.020_bib118","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.bbmt.2015.02.011","article-title":"Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines","volume":"21","author":"Aldenhoven","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.ymthe.2020.11.020_bib119","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1182\/blood-2010-04-278234","article-title":"Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model","volume":"116","author":"Visigalli","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.11.020_bib120","series-title":"First-in-human phase I\/II clinical trial of hematopoietic stem cell-gene therapy for mucopolysaccharidosis type I, Hurler (MPS-IH): preliminary evidence of extensive metabolic correction","author":"Bernardo","year":"2020"},{"key":"10.1016\/j.ymthe.2020.11.020_bib121","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1038\/mt.2013.141","article-title":"Myeloid\/microglial driven autologous hematopoietic stem cell gene therapy corrects a neuronopathic lysosomal disease","volume":"21","author":"Sergijenko","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.11.020_bib122","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/brain\/awx311","article-title":"Macrophage enzyme and reduced inflammation drive brain correction of mucopolysaccharidosis IIIB by stem cell gene therapy","volume":"141","author":"Holley","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.ymthe.2020.11.020_bib123","doi-asserted-by":"crossref","first-page":"489","DOI":"10.15252\/emmm.201505850","article-title":"Pervasive supply of therapeutic lysosomal enzymes in the CNS of normal and Krabbe-affected non-human primates by intracerebral lentiviral gene therapy","volume":"8","author":"Meneghini","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymthe.2020.11.020_bib124","doi-asserted-by":"crossref","first-page":"e1701211","DOI":"10.1126\/sciadv.1701211","article-title":"Intracerebroventricular delivery of hematopoietic progenitors results in rapid and robust engraftment of microglia-like cells","volume":"3","author":"Capotondo","year":"2017","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2020.11.020_bib125","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13023-018-0791-9","article-title":"Gene therapy in rare diseases: the benefits and challenges of developing a patient-centric registry for Strimvelis in ADA-SCID","volume":"13","author":"Stirnadel-Farrant","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymthe.2020.11.020_bib126","doi-asserted-by":"crossref","first-page":"eaap9630","DOI":"10.1126\/scitranslmed.aap9630","article-title":"Hematopoietic stem cell transplantation in its 60s: a platform for cellular therapies","volume":"10","author":"Chabannon","year":"2018","journal-title":"Sci. Transl. Med."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001620306183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001620306183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:03:22Z","timestamp":1761501802000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001620306183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":130,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S1525001620306183"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2020.11.020","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on Clinical Ex\u00a0Vivo Hematopoietic Stem Cell Gene Therapy for Inherited Monogenic Diseases","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2020.11.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors.","name":"copyright","label":"Copyright"}]}}